B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
PHASE1
This phase I trial tests safety, side effects and best dose of B-cell activ...
Tissue Alterations in Aggressive and Chronic Periodontitis
N/A
Present study intended to compare diseased and healthy sites in chronic and...
Status
Completed
Location
Gaziosmanpasa University Faculty of Dentistry
Start Date
2017-02-01
Trial ID
NCT03625414
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
PHASE2
This phase II clinical trial tests a chemotherapy regimen (dose-adjusted et...
Status
Active Not Recruiting
Location
Fred Hutch/University of Washington Cancer Consortium
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
PHASE2
This phase II trial studies how well inotuzumab ozogamicin works in treatin...